Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Exactly!
FWIW My take.
They clearly were able to cap this yesterday. They did not raise the bid and ask according to market forces and deterred volume buying from continuing. Should of closed over .04 IMO or at least .035. I don't think they can drive it down much more. On the plus side
1) Loan means no more dilution and validates revenues 200 million plus.
2) We know we are waiting on another loan approval which seems certain now IMO and a possible pre-purchase both will increase buying pressure here in the short term. I do not think this was a one day run. I still see a short term increase here.
3) Next month revenue numbers will start to trickle in. I know they are deliberately moving slow to make sure distribution channels are running smoothly prior to full scale production but any revenue is a plus. Each quarter will see growth IMO.
4) The factory will be completed in the spring (6-months)the latest so every day that we move closer to completion will slightly improve bullish sentiments. Time is on our side here.
5) They can only hold this down so long. The company keeps delivering on the August PR and if they continue every quarter this stock should see a higher trading range.
I am not loyal to a stock here. I am betting the odds and they are in our favor. This is just my take.
Smartmoney77
Not even the MM's? They deserve it....
Look at his post history. It says it all.
Absolutely! We'll PM details.
Booked my flight today. I want to find out about some of these other drugs coming down the pipeline.
I've learned that they are way off too. Sometimes they post sell on the daily and buy on the weekly for the same stock.
OK. XKEM stinks they only got a million more than they asked for? Come on! UPS Capital, the U.S. Import Export bank please....200 million plus in future revenues validated by two governments.... Sounds like some flim flam pump and dump operation to me...dahh..... J/K to those that didn't realize it....
You got to like the extra million too!
I was going to subscride too the newsleter too! J/K....
Briboy
You're asking people to make decisions for you. If you are frustrated change the way you think. I would suggest that when the stock doubles up from where you bought it sell your initial investment and let the rest ride. Then you can't really lose. If you don't think it will double up then sell when you feel comfortable and let a smaller portion of your investment ride. In either case you can't lose money and can make money off of the long term success of the company.
Myself I will probably not take my investment off the table until we are above .10 but I will follow the trend of the stock and may do so at a higher or lower number and then let the rest ride.
Good Luck
Smartmoney
SLJB is a great stock but so is XKEM. No reason to bash here bud. Besides,you're kind of peeing into the wind to put it politely....
Look at the start of the last run, June 1st, 2nd, and 3rd on the chart to get an idea where we are going IMO.
Watch this fly when .035 falls.
Absolutely because the only reason to give this loan is future revenues! 200 million plus!
It's Go Time! As in giddy up!
U.S. Ex-Im Bank has Approved Comprehensive Guarantee to Support $9.38 Million Loan from UPS Capital to Xechem Pharmaceuticals Nigeria
Wednesday October 18, 12:46 pm ET
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Xechem International, Inc. (OTC BB: XKEM - News) announced today that the United States Export Import (Ex-Im) Bank, the official credit export agency of the United States, has approved a Comprehensive Credit Guarantee to support a $9.38 million loan from UPS Capital Business Credit to Xechem Pharmaceuticals Nigeria, Ltd. (Xechem Nigeria). Two Nigerian banks, Access Bank Plc. and Diamond Bank, Plc., are to provide the required Nigerian local bank guarantees in favor of Ex-Im Bank.
ADVERTISEMENT
Funds Earmarked for Establishment of State-of-the-Art Pharmaceutical Facility in Sheda Science Village, Sheda, FCT, Abuja, Nigeria
The funds to be provided by UPS Capital under the Ex-Im guaranteed loan will be used to purchase the U.S. manufactured plant equipment and machinery needed by Xechem Nigeria to establish a state-of-the-art pharmaceutical facility. The first phase of construction of the new facility began in July of this year. The total cost of the project is estimated at $12.45 million, of which $9.38 million will come from the U.S. loan. The expanded pharmaceutical facility, once completed, will enable Xechem Nigeria to produce commercial scale quantities of NICOSAN(TM), Xechem's breakthrough medicine for the prophylactic management of Sickle Cell Disease (SCD).
Xechem Nigeria received regulatory approval for the manufacture, sales and marketing of NICOSAN(TM) from Nigeria's National Agency for Food and Drug Administration and Control (NAFDAC) on July 3rd, 2006, and officially launched the drug just a few days later at a ceremony presided over by His Excellency, General Olusegun Obasanjo, the President of Nigeria. The drug is currently being produced by Xechem Nigeria in limited quantities at its pilot-scale facility in Abuja.
Dr. Ramesh Pandey, Chairman and CEO of the Xechem Companies said, "We are very pleased that this most anticipated guarantee from the U.S. Ex-Im Bank has now been approved and that we can now accelerate pursuit of our dream of building what we believe will be one of the finest state-of-the-art cGMP standard pharmaceutical facilities in Nigeria. Even more importantly, the Ex-Im guaranteed loan will help insure that we can produce commercial scale quantities of NICOSAN(TM) to meet the needs of the millions of people afflicted with this terrible disease. We are very grateful to Ex-Im Bank, UPS Business Credit, Access Bank and Diamond Bank, as well as our financial consultants, Financialbridge, Inc., for their support for this important project and for helping us make the dream a reality."
About Sickle Cell Disease
Sickle Cell Disease (SCD) is an inherited blood disorder caused by an abnormality in the hemoglobin molecule. Patients with the disease often produce stiff, abnormally shaped red blood cells that often do not flow freely through the blood vessels. This can create clogs in the vessels, which in turn can cut off the flow of normal hemoglobin and oxygen to parts of the body, and can cause severe painful attacks or "crises", damage to various organs and shortened life spans. People with SCD often suffer unpredictable painful crises several times a year lasting from a few hours to a week or more. In the US, there are approximately 80,000 patients with SCD. In Nigeria, that number is believed to be approximately 4 million, with an estimated 10 - 12 million sufferers throughout the African continent. Worldwide, at least 16 million individuals are believed to be afflicted with SCD.
About Xechem
Xechem International is a development stage biopharmaceutical company working on Sickle Cell Disease (SCD), antimalarials, and antiviral (including AIDS), anticancer, antifungal and antibacterial products from natural sources, including microbial and marine organisms. Its primary focus is on the development of phyto-pharmaceuticals (Natural Herbal Drugs) and other proprietary technologies, including those used in the treatment of orphan diseases. Xechem's mission is to bring relief to the millions of people who suffer from these diseases. Its recent focus and resources have been directed primarily toward the development and launch of NICOSAN(TM) (named HEMOXIN(TM) in the US and Europe) for the prophylactic management of Sickle Cell Disease (SCD). With the recent Nigerian regulatory approval of NICOSAN(TM), Xechem is now scaling-up the commercialization of the drug in Nigeria and making preparations for the pursuit of US FDA and European regulatory approval. In addition to NICOSAN(TM), Xechem is also working on another sickle cell compound, 5-HMF, which it has licensed from Virginia Commonwealth University.
Forward Looking Statements
This press release contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward looking statements involve known and unknown risks and uncertainties.
Go back to Doctor Pandey's Auguest PR he lays it out there. This is amazing! 200 million in future revenues validated by U.S. Import Export bank. Awesome!!!
Nope factory will be completed spring the latest for full scale production. Plus they're already producing now and have limited people on the drug. This is awesome!!!!!!!!!
This is huge! No more dilution! 200 million in revenues validated by U.S. Import Export Bank.......
I think we will be testing the highs of early July sooner than expected. We have another loan and a possible pre-purchase coming. This is fun now!
We were at .035 a couple weeks ago on nothing. We're blowing way past that today IMO.
Hell no we got another loan coming and a possible pre-purchase!
Do the shorters covering their buts have to call in a trade right now!!!:))))
I thought Nigeria would come first. U.S. Import Export adds a lot more credibility to those 200 million dollar projected revenue numbers IMO.
Short Cover for real? Guess we're going to find out!
They're going to be chasing this for weeks. IMO.
Giddy UP! 200 Million in Revenues just rubber stamped!!!
That's an extra million from UPS. I hope the Nigeria loan is that generous!!!!
http://biz.yahoo.com/bw/061018/20061018005758.html?.v=1
Press Release Source: Xechem International, Inc.
U.S. Ex-Im Bank has Approved Comprehensive Guarantee to Support $9.38 Million Loan from UPS Capital to Xechem Pharmaceuticals Nigeria
Wednesday October 18, 12:46 pm ET
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Xechem International, Inc. (OTC BB: XKEM - News) announced today that the United States Export Import (Ex-Im) Bank, the official credit export agency of the United States, has approved a Comprehensive Credit Guarantee to support a $9.38 million loan from UPS Capital Business Credit to Xechem Pharmaceuticals Nigeria, Ltd. (Xechem Nigeria). Two Nigerian banks, Access Bank Plc. and Diamond Bank, Plc., are to provide the required Nigerian local bank guarantees in favor of Ex-Im Bank.
ADVERTISEMENT
Funds Earmarked for Establishment of State-of-the-Art Pharmaceutical Facility in Sheda Science Village, Sheda, FCT, Abuja, Nigeria
The funds to be provided by UPS Capital under the Ex-Im guaranteed loan will be used to purchase the U.S. manufactured plant equipment and machinery needed by Xechem Nigeria to establish a state-of-the-art pharmaceutical facility. The first phase of construction of the new facility began in July of this year. The total cost of the project is estimated at $12.45 million, of which $9.38 million will come from the U.S. loan. The expanded pharmaceutical facility, once completed, will enable Xechem Nigeria to produce commercial scale quantities of NICOSAN(TM), Xechem's breakthrough medicine for the prophylactic management of Sickle Cell Disease (SCD).
Xechem Nigeria received regulatory approval for the manufacture, sales and marketing of NICOSAN(TM) from Nigeria's National Agency for Food and Drug Administration and Control (NAFDAC) on July 3rd, 2006, and officially launched the drug just a few days later at a ceremony presided over by His Excellency, General Olusegun Obasanjo, the President of Nigeria. The drug is currently being produced by Xechem Nigeria in limited quantities at its pilot-scale facility in Abuja.
Dr. Ramesh Pandey, Chairman and CEO of the Xechem Companies said, "We are very pleased that this most anticipated guarantee from the U.S. Ex-Im Bank has now been approved and that we can now accelerate pursuit of our dream of building what we believe will be one of the finest state-of-the-art cGMP standard pharmaceutical facilities in Nigeria. Even more importantly, the Ex-Im guaranteed loan will help insure that we can produce commercial scale quantities of NICOSAN(TM) to meet the needs of the millions of people afflicted with this terrible disease. We are very grateful to Ex-Im Bank, UPS Business Credit, Access Bank and Diamond Bank, as well as our financial consultants, Financialbridge, Inc., for their support for this important project and for helping us make the dream a reality."
About Sickle Cell Disease
Sickle Cell Disease (SCD) is an inherited blood disorder caused by an abnormality in the hemoglobin molecule. Patients with the disease often produce stiff, abnormally shaped red blood cells that often do not flow freely through the blood vessels. This can create clogs in the vessels, which in turn can cut off the flow of normal hemoglobin and oxygen to parts of the body, and can cause severe painful attacks or "crises", damage to various organs and shortened life spans. People with SCD often suffer unpredictable painful crises several times a year lasting from a few hours to a week or more. In the US, there are approximately 80,000 patients with SCD. In Nigeria, that number is believed to be approximately 4 million, with an estimated 10 - 12 million sufferers throughout the African continent. Worldwide, at least 16 million individuals are believed to be afflicted with SCD.
About Xechem
Xechem International is a development stage biopharmaceutical company working on Sickle Cell Disease (SCD), antimalarials, and antiviral (including AIDS), anticancer, antifungal and antibacterial products from natural sources, including microbial and marine organisms. Its primary focus is on the development of phyto-pharmaceuticals (Natural Herbal Drugs) and other proprietary technologies, including those used in the treatment of orphan diseases. Xechem's mission is to bring relief to the millions of people who suffer from these diseases. Its recent focus and resources have been directed primarily toward the development and launch of NICOSAN(TM) (named HEMOXIN(TM) in the US and Europe) for the prophylactic management of Sickle Cell Disease (SCD). With the recent Nigerian regulatory approval of NICOSAN(TM), Xechem is now scaling-up the commercialization of the drug in Nigeria and making preparations for the pursuit of US FDA and European regulatory approval. In addition to NICOSAN(TM), Xechem is also working on another sickle cell compound, 5-HMF, which it has licensed from Virginia Commonwealth University.
Forward Looking Statements
This press release contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward looking statements involve known and unknown risks and uncertainties.
Contact:
Xechem International, Inc
Stephen Burg, Director, 707-425-8855
--------------------------------------------------------------------------------
Source: Xechem International, Inc.
She's going to blow!!!
Yeah I was just thinking the HOD is about to get overun but I am glad you feel good too because you are better at these short term predictions when you're right...lol
Is that on wire transfers? That is BS change them. Schwab gives immediate access to bank checks let alone wires.
I still haven't decided if I'm going. My issue is that if I fly up I'll miss the action for a couple days and there might be a lot of action at that time.
My target has been .25- .28 since I started getting back in in Late July. It may be a slower ride up this time but more stable. I think .15-.18 is a fair target but I suggest everybody follow the momentum and take their money off the table on the way up. I wouldn't complain with .7-.10 either but it all depends on timing. If they get one loan it then becomes almost certain inn my mind that the next is coming and if it comes a month later we're going up until the second one hits IMO. Any pre-purchase and it becomes the high end numbers IMO. We do have a higher base here.
OMG I'm in. It almost gives us the same advantage as the MM's, well almost. 100 share trades here I come lol
I saw your post about Bank Of America and printed it. I don't want to change anything just right now but if they have a platform somewhat as good as streetsmart pro does with Schwab I'll go with free trades anyday!
knowlesmsncom
I think the PPS is going up after the meeting. Everyone knows the A/S will pass and they've known it since Labor Day. Once the meeting is passed investors will realize the sky hasn't fallen and they will start coming back in. I do agree that what we are seeing here is accumulation and the flipping going on here is negligible because of the low volume.
I mean some guy touting his TA skills talking about flipping on yesterdays volume is silly. I hold more shares than was traded yesterday what did the guy make a few hundred bucks. We are seeing a few longs getting scared and unloading but not many or we'd have real volume.
I do not think they can shake this much lower subtle bashers aside. I have been told that "honestly, dilution to fund the factory was never even discussed in this building".
I agree it is buy time right now but I've noticed that a lot of people buy high and sell low. Not a strategy for succes lol.
GLTY
Smartmoney
Yeah, we're not sitting on the floor, we're sitting on the basement floor. Seems like volume dries up as it goes down here to these levels then it inches back up.
Nope not concerned and the PPS will go up IMO but thanks for asking. The market has already factored in the increase since we all know it will be passed.